Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + mobocertinib
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Bevacizumab + mobocertinib is a combination therapy being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR exon 20 insertion mutations. Bevacizumab is a monoclonal antibody that selectively targets vascular endothelial growth factor (VEGF) and inhibits angiogenesis mechanisms crucial in cancer progression. Mobocertinib is an oral EGFR tyrosine kinase inhibitor specifically designed to target EGFR exon 20 insertions. This combination has shown promise in treating patients with EGFR exon 20-mutated NSCLC who developed resistance to amivantamab.
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFA (Vascular endothelial growth factor A)EGFR ex20ins (Epidermal growth factor receptor exon 20 mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on bevacizumab + mobocertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + mobocertinib.